Biosimilars are very similar versions of approved and authorized medicines. Clinically inactive components will have minor differences, but there are no significant differences between the biosimilar and the original product in terms of potency, purity and safety.
Protein biopharmaceuticals are being developed at an explosive rate and have attracted great inte...
Over the past decade, notable advances in the characterization and control of post translational modifications (PTMs) to enhance therapeutic properties have continued to drive the development of man...
"Works stably in high-throughput 24/7 routine analysis. Only the thermostat in the autosampler has c..."Mareike Reichel, Eurofins WEJ Contaminants
Analytical Quality by Design (AQbD) will start to play a more predominant role in analytic...
.jpg.ashx?width=150&bgcolor=white)
